The size of India’s insulin market was an estimated Rs 4,404 crore in April this year, with Indian players making steady ...

The European Commission has granted marketing authorisation for Novo Nordisk’s adult diabetes treatments Tresiba and Ryzodeg. The approval covers all 27 European Union member states. Tresiba ...

NEW DELHI: After months of sluggish sales, strong demand for derma and cardiac drugs drove the organised pharma retail market to double-digit growth in Nov, with heavy pollution in several parts ...

The second-largest insulin brand also comes from Novo Nordisk’s portfolio, Ryzodeg, with a MAT of Rs 593 crore, followed by Sanofi’s Lantus. Why is human insulin no longer a priority? In high-income ...

Clin Drug Invest. 2004;24(12):695-717.